Research/art/teacher profile of a person
Name and surname:
Mgr. Peter Šramel, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Šramel
I.2 - Name
Peter
I.3 - Degrees
Mgr., PhD.
I.4 - Year of birth
1989
I.5 - Name of the workplace
Comenius University in Bratislava, Faculty of Natural Sciences
I.6 - Address of the workplace
Mlynská dolina, Ilkovičova 6, 842 15 Bratislava 4
I.7 - Position
Assistant Professor
I.8 - E-mail address
peter.sramel@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/29530
I.10 - Name of the study field in which a person works at the university
17. chemistry
I.11 - ORCID iD
0000-0003-0525-6868

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences
II.b - Year
2011
II.c - Study field and programme
Biochemistry
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences
II.b - Year
2013
II.c - Study field and programme
Organic and bioorganic chemistry
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences; Université de Strasbourg, ECPM (Co-tutelle)
II.b - Year
2017
II.c - Study field and programme
Organic and medicinal chemistry
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Assistant Professor Comenius University in Bratislava, Faculty of Natural Sciences 2018 - present (unpaid leave)
Scientist (part-time) Centre of experimental medicine, SAS 2019 - present (unpaid leave)
Scientist University of Pardubice, Faculty of chemical technology 2024 - present

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Basics in the Python programming language ITCourse, SAS 2021
Training School, COST Action CM1106 Universidade de Lisboa, Lisbon, Portugal 2015
X EWDD, European Workshop in Drug Design Università degli Studi di Siena, Siena, Italy 2015

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
0
V.4.c - Dissertation (third degree)
0
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
5
V.4.b - Diploma (second degree)
4
V.4.c - Dissertation (third degree)
0
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Bioorganic chemistry (2) Organic and bioorganic chemistry 1. Mgr 17. chemistry

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
16
VI.1.b - Over the last six years
8
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
6
VI.1.b - Over the last six years
4
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
57
VI.1.b - Over the last six years
57
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
57
VI.1.b - Over the last six years
57
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
0
VI.1.b - Over the last six years
0
VI.2 - The most significant research/artistic/other outputs
1

Krátky, M.; Šramel, P.; Boďo, P.; Šoltésová-Prnová, M.; Kováčiková, L., Májeková, M.; Vinšová, J.; Štefek, M. Novel Rhodanine-based Inhibitors of Aldose Reductase of non-Acidic Nature with P-Hydroxybenzylidene Functional Group. Eur. J. Med. Chem. 2023, 246, 114922, DOI: 10.1016/j.ejmech.2022.114922.

2

Hlaváč, M.; Kováčiková, L.; Prnová Šoltésová, M.; Šramel, P.; Addová, G.; Májeková, M.; Hanquet, G.; Boháč, A.; Štefek, M. Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur / Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. J. Med. Chem. 2020, 63, 369 – 381, DOI: 10.1021/acs.jmedchem.9b01747.

3

Murár, M.; Dobiaš, J.; Šramel, P.; Addová, G.; Hanquet, G.; Boháč, A. Novel CLK1 Inhibitors Based on N-Aryloxazol-2-amine Skeleton – A Possible Way to Dual VEGFR2 TK / CLK Ligands. Eur. J. Med. Chem. 2017, 126, 754 – 761, DOI: 10.1016//j.ejmech.2016.11.003.

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Krátky, M.; Šramel, P.; Boďo, P.; Šoltésová-Prnová, M.; Kováčiková, L., Májeková, M.; Vinšová, J.; Štefek, M. Novel Rhodanine-based Inhibitors of Aldose Reductase of non-Acidic Nature with P-Hydroxybenzylidene Functional Group. Eur. J. Med. Chem. 2023, 246, 114922, DOI: 10.1016/j.ejmech.2022.114922.

2

Hlaváč, M.; Kováčiková, L.; Prnová Šoltésová, M.; Šramel, P.; Addová, G.; Májeková, M.; Hanquet, G.; Boháč, A.; Štefek, M. Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur / Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. J. Med. Chem. 2020, 63, 369 - 381, DOI: 10.1021/acs.jmedchem.9b01747.

3

Murár, M.; Dobiaš, J.; Šramel, P.; Addová, G.; Hanquet, G.; Boháč, A. Novel CLK1 Inhibitors Based on N-Aryloxazol-2-amine Skeleton – A Possible Way to Dual VEGFR2 TK / CLK Ligands. Eur. J. Med. Chem. 2017, 126, 754 - 761, DOI: 10.1016//j.ejmech.2016.11.003.

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Song, M.; Pang, L.; Zhang, M.; Qu, Y.; Laster Vaughn, K.; Dong, Z. Cdc2-like Kinases: Structure, Biological Function and Therapautic Targets for Diseases. Sig. Transduct. Target. Ther. 2023, 8, 148, DOI: 10.1038/s41392-023-01409-4.

2

Qin, Z.; Qin, L.; Feng, Xi.; Li, Z.; Bian, J. Developement of Cdc2-like Kinase 2 Inhibitors: Achievments and Future Directions. J. Med. Chem. 2021, 64, 13191 - 13211, DOI: 10.1021/acs.jmedchem.1c00985.

3

Zhao, W.-H.; Xu, J.-H.; Tangandanchu, V. K. R.; Zhou, C.-H. Thiazolyl Hydrazineylidenyl Indolones as Unique Potential Multitargeting Broad-Spectrum Antimicrobial Agents. Eur. J. Med. Chem. 2023, 256, 115452, DOI: 10.1016/j.ejmech.2023.115452.

4

Yang, T.; Yang, Y.; Chen, Y.; Tang, M.; Shi, M.; Tian, Y.; Yuan, X.; Yang, Z.; Chen, L. Rational Design and Appraisal of Selective Cdc2-Like Kinase 1 (Clk1) Inhibitors as Novel Autophagy Inducers for the Treatment of Acute Liver Injury (ALI). Eur. J. Med. Chem. 2023, 250, 115168, DOI: 10.1016/j.ejmech.2023.115168.

5

Kousaxidis, A.; Petrou, A.; Lavrentaki, V.; Fesatidou, M.; Nicolaou, I.; Geronikaki, A. Aldose Reductase and Protein Tyrosine Phosphatase 1B Inhibitors as a Promising Therapeutic Approach for Diabetes Mellitus. Eur. J. Med. Chem. 2020, 207, 112742, DOI: 10.1016/j.ejmech.2020.112742.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Fine organometallic compounds for the green synthesis and catalysis; 2022; APVV-22-0167

2

A multi-target approach to the diverse molecular mechanisms of diabetic complications and other diseases related to glucose toxicity; 2020; APVV-20-0543

3

Ligand induced modulation of calcium pump SERCA - study of mechanism and design of new compounds; 2022 - 2026; VEGA 2/0103/22

4

New substances for the prevention and therapy of diseases caused by glucose toxicity; 2018 - 2021; VEGA 2/0127/18

5

Medicinal chemistry - an eficient development of inhibitors of selected key biological targets connected with tumor progression; 2018 - 2021; VEGA 1/0670/18

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Université de Strasbourg, ECPM 25 Rue Becquerel, 67087, Strasbourg, France 2014-2017 (total of 21 months) Co-tutelle de Thése (PhD study under double supervision)
University of Pardubice, Faculty of chemical technology Studentská 95, 532 10, Pardubice, Czech republic 2024 - present Postdoc

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

An author of the Chemistry Olympiad tasks (home, school and regional round), Organic Chemistry, cat, B, 2020 - present

A teaching experience in advanced organic chemistry excercises at a foreign university (Université de Strasbourg, ECPM, France), 2014 - 2016

Date of last update
2024-11-07